Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HRMY stock price vs AOS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AOS's multiple
Needs AOS P/E.
Implied fair value · at HRMY's multiple
Needs HRMY P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HRMY FY 2025 (ended Dec 31, 2025) · AOS FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 2.13x · EV / EBITDA 7.27x
Capital structure 96% equity / 4% debt · EV / Revenue 1.20x · EV / EBITDA 6.06x
AOS carries the larger enterprise value at $4.58B against $1.85B; AOS trades on the lower EV / Revenue multiple (1.20x vs 2.13x); AOS on the lower EV / EBITDA (6.06x vs 7.27x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HARMONY BIOSCIENCES HOLDINGS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
A. O. Smith Corporation · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.19x
0.11x
Net debt / EBITDA
Leverage against operating earnings
-2.41x
0.01x
Cash and equivalents
Liquid reserves on the balance sheet
$775.34M
$193.20M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
HRMY vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
HRMY vs SUPN
Intra-Cellular Therapies, Inc.
HRMY vs ITCI
ACADIA PHARMACEUTICALS INC
HRMY vs ACAD
Vanda Pharmaceuticals Inc.
HRMY vs VNDA
LivaNova PLC
HRMY vs LIVN
WATTS WATER TECHNOLOGIES INC
HRMY vs WTS
Mueller Water Products, Inc.
HRMY vs MWA
LENNOX INTERNATIONAL INC
HRMY vs LII
Avery Dennison Corp
HRMY vs AVY
LEGGETT & PLATT INC
HRMY vs LEG
METTLER TOLEDO INTERNATIONAL INC/
HRMY vs MTD
$163.66M
$197.30M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
